The company has also developed software that will enable automated melt curve analysis on Cepheid's existing GeneXpert platforms.
The tests are twice as fast as the firm's Xpert line and run on Cepheid's flagship GeneXpert system.
Overall growth was driven by the company's diagnostics segment, which rose 11 percent, while life sciences improved 6 percent
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
To develop the test, the firm said it used a library of MRSA strains collected around the world, and included components that reduce false positive results.
The evidence-based guidelines for testing individuals at risk of latent or active TB infection include recommendations on interferon-gamma release and molecular assays.
Cepheid noted that the cartridge is not currently part of its five-year commercial plan, but the firm is in discussions with outside parties to push development forward.
Cepheid is now an indirect wholly owned subsidiary of Danaher, and the firm's stock will no longer be traded on the Nasdaq.
The firm, which is in the process of being acquired by Danaher, reported strong revenue growth for both its consumables and systems.
The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.
A new study catalogues the genome and evolutionary history of the oak family, UPI reports.
Dog DNA testing is a growing market, but there's still a lot of uncertainty about the accuracy of the results, the Boston Globe says.
A University of South Florida researcher is testing bone fragments to determine if they belong to Amelia Earhart.
In Cell this week: antisense Piwi-interacting RNA responses to endogenous retroviruses, proteomic patterns in hepatocellular carcinoma, and more.